• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel) (Amendment)

    2/14/22 3:23:08 PM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CANF alert in real time by email
    SC 13G/A 1 tm226115d36_sc13ga.htm SC 13G/A

     

    CUSIP No: 13471N201

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 2)*

     

    Can-Fite BioPharma Ltd.

    (Name of Issuer)

     

    Ordinary Shares, NIS 0.25 par value per share

    (Title of Class of Securities)

     

    13471N201

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨      Rule 13d-1(b)

    x     Rule 13d-1(c)

    ¨      Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No: 13471N201

     

      (1)

    NAMES OF REPORTING PERSONS

     

    CVI Investments, Inc.

     

      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
          (a)    ¨
          (b)    ¨
           
      (3) SEC USE ONLY
         
      (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    (5) SOLE VOTING POWER
     
    0
     
     
    (6) SHARED VOTING POWER **
     
    23,161,650
     
     
    (7) SOLE DISPOSITIVE POWER
     
    0
     
     
    (8) SHARED DISPOSITIVE POWER **
     
    23,161,650
     

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
        23,161,650
         
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨ 
         
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
         
        3.7%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
         
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 13471N201

     

      (1)

    NAMES OF REPORTING PERSONS

     

    Heights Capital Management, Inc.

     

      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
          (a)    ¨
          (b)    ¨
           
      (3) SEC USE ONLY
         
      (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    (5) SOLE VOTING POWER
     
    0
     
     
    (6) SHARED VOTING POWER **
     
    23,161,650
     
     
    (7) SOLE DISPOSITIVE POWER
     
    0
     
     
    (8) SHARED DISPOSITIVE POWER **
     
    23,161,650

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
        23,161,650
         
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨ 
         
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
         
        3.7%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
         
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 13471N201

     

    Item 1.

     

    (a)  Name of Issuer

     

    Can-Fite BioPharma Ltd. (the “Company”)

     

    (b)  Address of Issuer’s Principal Executive Offices

     

    10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petach-Tikva 4951778, Israel

     

    Item 2(a). Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the ordinary shares of the Company, NIS 0.25 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House 

    South Church Street

    George Town 

    Grand Cayman

    KY1-1104 

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c). Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)  Title of Class of Securities

     

    Ordinary shares, NIS 0.25 par value per share

     

    Item 2(e)  CUSIP Number

     

    13471N201. The CUSIP Number applies to the American Depositary Shares, each of which represents thirty (30) Shares.

     

     

     

     

    CUSIP No: 13471N201

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
         
    (b) ¨  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ¨  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d) ¨  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e) ¨  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ¨  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ¨  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ¨  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ¨  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) ¨  Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of American Depositary Shares (“ADSs”), each of which represents thirty (30) Shares, that are issuable upon the exercise of warrants to purchase ADSs.

     

    The Company’s Prospectus (Registration No. 333-262055), filed on January 14, 2022, indicates there were 601,996,293 Shares outstanding as of September 30, 2021.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

     

     

     

    CUSIP No: 13471N201

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 13471N201

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 11, 2022

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         

    By: Heights Capital Management, Inc.
    pursuant to a Limited Power of Attorney, a copy of which was previously filed

      By: /s/ Brian Sopinsky
      Name: Brian Sopinsky
      Title: Secretary

     

    By: /s/ Brian Sopinsky  
    Name: Brian Sopinsky  
    Title: Secretary  

     

     

     

     

    CUSIP No: 13471N201

     

    EXHIBIT INDEX

     

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*

     

    *Previously filed

     

     

     

    Get the next $CANF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CANF

    DatePrice TargetRatingAnalyst
    6/24/2021$5.00Buy
    Aegis Capital
    More analyst ratings

    $CANF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

      SC 13G/A - Can-Fite BioPharma Ltd. (0001536196) (Subject)

      11/14/24 4:48:49 PM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

      SC 13G - Can-Fite BioPharma Ltd. (0001536196) (Subject)

      2/14/24 3:32:17 PM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel) (Amendment)

      SC 13G/A - Can-Fite BioPharma Ltd. (0001536196) (Subject)

      2/14/22 3:23:08 PM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CANF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aegis Capital initiated coverage on Can Fite Biofarma with a new price target

      Aegis Capital initiated coverage of Can Fite Biofarma with a rating of Buy and set a new price target of $5.00

      6/24/21 10:10:03 AM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CANF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis

      Ramat Gan, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, today announced that, it has raised $175 million in funding to date. These funds have enabled the advancement of its lead drug candidates, Namodenoson and Piclidenoson, into pivotal Phase III studies for liver cancer and psoriasis, respectively. Can-Fite is a recognized leader in the development of small-molecule therapeutics targeting the A3 adenosine receptor (A3AR), which is highly expressed in both inflammatory and cancer cells. Namodenoson, an orally bioavailab

      5/5/25 8:00:00 AM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

      Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that leading Medical Centers in the US are approaching the FDA, asking for compassionate use approval to treat patients with pancreatic carcinoma with the company oncological drug Namodenoson. Namodenoson has recently received FDA approval for its first single-patient compassionate use treatment, marking a significant milestone in its clinical journey. This approval has sparked growing interest from oncologists at leading U.S. medical center

      4/17/25 8:55:00 AM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

      RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases ("Can-Fite" or the "Company"), today announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 of the Company's American Depositary Shares ("ADSs"), at a purchase price of $1.20 per ADS, in a registered direct offering. The offering is expected to close on or about April 15, 2025, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross

      4/14/25 2:28:14 PM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CANF
    SEC Filings

    See more
    • SEC Form 6-K filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

      6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)

      5/16/25 4:15:21 PM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

      424B5 - Can-Fite BioPharma Ltd. (0001536196) (Filer)

      5/9/25 4:30:39 PM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

      6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)

      5/5/25 8:10:01 AM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CANF
    Financials

    Live finance-specific insights

    See more
    • 60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Can-Fite BioPharma Ltd. (NYSE:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:SXTP: https://www.redchip.com/assets/access/sxtp_accessCANF: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on

      11/22/24 9:00:00 AM ET
      $CANF
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE:OSTX) and Can-Fite BioPharma Ltd. (NYSE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 10, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:OS Therapies: https://www.redchip.com/assets/access/ostx_accessCan-Fite: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Paul Romness, Chairman and CEO of OS Therapies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate

      8/9/24 9:00:00 AM ET
      $CANF
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Can-Fite: https://www.redchip.com/assets/access/canf_accessNutriband: https://www.redchip.com/assets/access/ntrb_accessIn an exclusive interview, Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, appears on the RedChip Small Stocks, Big Money™ show on Blo

      5/10/24 9:00:00 AM ET
      $CANF
      $NTRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties